{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T18:11:36Z","timestamp":1755799896294,"version":"3.44.0"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T00:00:00Z","timestamp":1755648000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Inflammatory breast cancer (IBC) is a rare and aggressive breast cancer type, accounting for 5-7% of breast cancer-related deaths, and its bilateral involvement is exceedingly uncommon. We report a case of metachronous bilateral IBC in a 50-year-old premenopausal woman with Charcot-Marie-Tooth disease, offering novel insight into the diagnostic, therapeutic, and molecular challenges of this condition. The patient initially presented with acute right breast erythema, skin thickening, and <jats:italic>peau d\u2019orange<\/jats:italic>, followed by contralateral breast involvement with similar symptoms. Disease progression occurred with changes in receptor status and eventual loss of hormone receptor (HR) expression. The initial diagnosis was stage IIIB HR-positive\/HER2-negative IBC. The patient underwent neoadjuvant chemotherapy, surgery, adjuvant radiotherapy, and endocrine therapy. However, the patient experienced a contralateral recurrence after 11 months of disease-free survival. Subsequent management involved multiple systemic therapies, including targeted therapy after next-generation sequencing analysis revealed a <jats:italic>PIK3CA<\/jats:italic> mutation. Although some clinical benefit was achieved, the disease continued to progress. Ultimately, the patient passed away four years after the initial diagnosis. This case underscores the aggressive and recurrent nature of bilateral IBC, its diagnostic complexity, and the importance of molecular profiling in guiding targeted treatment. It highlights the need for clinical vigilance, timely reassessment of tumor biology, and individualized multimodal care in managing rare and evolving presentations of IBC.<\/jats:p>","DOI":"10.3389\/fonc.2025.1595513","type":"journal-article","created":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T05:36:10Z","timestamp":1755668170000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Double trouble, managing bilateral inflammatory breast cancer: a case report"],"prefix":"10.3389","volume":"15","author":[{"given":"Josep","family":"Sabat\u00e9-Ortega","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Ribera-Montserrat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonia","family":"del Barco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ariadna","family":"Roqu\u00e9-Lloveras","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roser","family":"Fort-Culillas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. Carme","family":"Carmona-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raquel","family":"Li\u00f1an","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emma","family":"Polonio-Alcal\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerard","family":"Carb\u00f3-Vilavedra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irma","family":"Ramos-Oliver","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabet","family":"Bujons-Buscarons","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Monta\u00f1\u00e9s-Ferrer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gemma","family":"Vi\u00f1as","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helena","family":"Pla-Juher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,8,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1177\/1758835920932674","article-title":"A large-cohort retrospective study of metastatic patterns and prognostic outcomes between inflammatory and non-inflammatory breast cancer","volume":"12","author":"Wang","year":"2020","journal-title":"Ther Adv Med Oncol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1016\/J.SUC.2018.03.009","article-title":"Inflammatory breast cancer: what to know about this unique, aggressive breast cancer","volume":"98","author":"Menta","year":"2018","journal-title":"Surg Clinics North America"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1007\/S10549-012-2133-2","article-title":"Inflammatory and non-inflammatory breast cancer survival by socioeconomic position in the Surveillance, Epidemiology, and End Results database, 1990\u20132008","volume":"134","author":"Schlichting","year":"2012","journal-title":"Breast Cancer Res Treat"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1007\/S10549-015-3436-X","article-title":"Overall survival differences between patients with inflammatory and noninflammatory breast cancer presenting with distant metastasis at diagnosis","volume":"152","author":"Fouad","year":"2015","journal-title":"Breast Cancer Res Treat"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/J.AJOG.2021.04.217","article-title":"Inflammatory breast cancer: early recognition and diagnosis is critical","volume":"225","author":"Hester","year":"2021","journal-title":"Am J Obstet Gynecol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.40101","article-title":"A case of bilateral inflammatory breast cancer","volume":"15","author":"Levy","year":"2023","journal-title":"Cureus"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/S10549-020-05785-1","article-title":"Obesity and related conditions and risk of inflammatory breast cancer: a nested case-control study","volume":"183","author":"Schairer","year":"2020","journal-title":"Breast Cancer Res Treat"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1007\/S10552-015-0712-3","article-title":"Epidemiological risk factors associated with inflammatory breast cancer subtypes","volume":"27","author":"Atkinson","year":"2016","journal-title":"Cancer Causes Control"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djt206","article-title":"Risk factors for inflammatory breast cancer and other invasive breast cancers","volume":"105","author":"Schairer","year":"2013","journal-title":"JNCI: J Natl Cancer Institute"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-023-13906-5","article-title":"Low rates of local-regional recurrence among inflammatory breast cancer patients after contemporary trimodal therapy","volume":"30","author":"Adesoye","year":"2023","journal-title":"Ann Surg Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/S10549-019-05363-0","article-title":"National trends of synchronous bilateral breast cancer incidence in the United States","volume":"178","author":"Sakai","year":"2019","journal-title":"Breast Cancer Res Treat"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02216-8","article-title":"Evolution of synchronous female bilateral breast cancers and response to treatment","volume":"29","author":"Hamy","year":"2023","journal-title":"Nat Med"},{"key":"B13","doi-asserted-by":"publisher","first-page":"67","DOI":"10.4103\/2321-4848.183345","article-title":"A rare case of triple negative synchronous bilateral invasive ductal carcinoma of breast","volume":"4","author":"Purkayastha","year":"2016","journal-title":"Arch Med Health Sci"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.22925","article-title":"HER2-positive inflammatory breast cancer challenges of clinical practices","volume":"14","author":"Magalh\u00e3es","year":"2022","journal-title":"Cureus"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2354.2009.01075.x","article-title":"Case report of bilateral inflammatory breast cancer","volume":"19","author":"Masannat","year":"2009","journal-title":"Eur J Cancer Care (Engl)"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1111\/tbj.12578","article-title":"A case of a bilateral inflammatory breast cancer: A case report","volume":"22","author":"Kurtz","year":"2016","journal-title":"Breast J"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.7786-21","article-title":"Bilateral inflammatory breast cancer that developed two years after treatment for triple-negative breast cancer","volume":"61","author":"Kawaguchi","year":"2022","journal-title":"Internal Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-010-1324-y","article-title":"Inflammatory breast cancer: high risk of contralateral breast cancer compared to comparably staged non-inflammatory breast cancer","volume":"129","author":"Schairer","year":"2011","journal-title":"Breast Cancer Res Treat"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jare.2020.08.014","article-title":"Update on systemic treatment for newly diagnosed inflammatory breast cancer","volume":"29","author":"Chainitikun","year":"2021","journal-title":"J Adv Res"},{"key":"B20","doi-asserted-by":"publisher","first-page":"e0189385","DOI":"10.1371\/journal.pone.0189385","article-title":"Incidence of inflammatory breast cancer in patients with clinical inflammatory breast symptoms","volume":"12","author":"Dabi","year":"2017","journal-title":"PloS One"},{"key":"B21","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.mri.2018.03.012","article-title":"Differentiating benign and Malignant inflammatory breast lesions: Value of T2 weighted and diffusion weighted MR images","volume":"50","author":"Kanao","year":"2018","journal-title":"Magn Reson Imaging"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.34145","article-title":"A case of advanced bilateral inflammatory breast cancer: A radiological perspective","volume":"15","author":"Salmanzadeh","year":"2023","journal-title":"Cureus"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-021-10522-z","article-title":"Current surgical management of inflammatory breast cancer","volume":"28","author":"Adesoye","year":"2021","journal-title":"Ann Surg Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2021.1929724","article-title":"Immune landscape of inflammatory breast cancer suggests vulnerability to immune checkpoint inhibitors","volume":"10","author":"Bertucci","year":"2021","journal-title":"Oncoimmunology"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2021.101026","article-title":"Gene expression profiles of inflammatory breast cancer reveal high heterogeneity across the epithelial-hybrid-mesenchymal spectrum","volume":"14","author":"Chakraborty","year":"2021","journal-title":"Transl Oncol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s13058-019-1108-1","article-title":"Infiltrating stromal immune cells in inflammatory breast cancer are associated with an improved outcome and increased PD-L1 expression","volume":"21","author":"Van Berckelaer","year":"2019","journal-title":"Breast Cancer Res"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2014.06.008","article-title":"Genomic profiling of inflammatory breast cancer: A review","volume":"23","author":"Bertucci","year":"2014","journal-title":"Breast"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMOA1813904","article-title":"Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer","volume":"380","author":"Andr\u00e9","year":"2019","journal-title":"N Engl J Med"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3390\/BIOMEDICINES11010109","article-title":"Targeting PI3K\/AKT\/mTOR pathway in breast cancer: from biology to clinical challenges","volume":"11","author":"Cerma","year":"2023","journal-title":"Biomedicines"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-3652","article-title":"FDA approval summary: alpelisib plus fulvestrant for patients with HR-positive, HER2-negative, PIK3CA-mutated, advanced or metastatic breast cancer","volume":"27","author":"Narayan","year":"2021","journal-title":"Clin Cancer Res"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1595513\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T05:36:11Z","timestamp":1755668171000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1595513\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,20]]},"references-count":30,"alternative-id":["10.3389\/fonc.2025.1595513"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1595513","relation":{},"ISSN":["2234-943X"],"issn-type":[{"type":"electronic","value":"2234-943X"}],"subject":[],"published":{"date-parts":[[2025,8,20]]},"article-number":"1595513"}}